Amy N Melsaether1, Eric Kim2, Eralda Mema3, James Babb4, Sungheon Gene Kim5. 1. Department of Radiology, NYU School of Medicine, 160 E34th St, 3rd Floor, New York, NY 10016, United States of America. Electronic address: amy.melsaether@mountsinai.org. 2. Department of Radiology, NYU School of Medicine, 160 E34th St, 3rd Floor, New York, NY 10016, United States of America. Electronic address: Eric.kim2@nyumc.org. 3. Department of Radiology, NYU School of Medicine, 160 E34th St, 3rd Floor, New York, NY 10016, United States of America. Electronic address: Eralda.mema@nyumc.org. 4. NYU School of Medicine and Center for Advanced Imaging and Innovation, (CAI2R), NYU School of Medicine, 660 1st Ave, 2nd Floor, New York, NY 10016, United States of America. Electronic address: james.babb@nyumc.org. 5. NYU School of Medicine and Center for Advanced Imaging and Innovation, (CAI2R), NYU School of Medicine, 660 1st Ave, 2nd Floor, New York, NY 10016, United States of America; Bernard and Irene Schwartz Center for Biomedical Imaging Department of Radiology, NYU School of Medicine, 660 1st Ave, 2nd Floor, New York, NY 10016, United States of America. Electronic address: Gene.kim@nyumc.org.
Abstract
BACKGROUND: Dynamic contrast enhanced (DCE) breast MRI is highly sensitive for breast cancer and requires gadolinium-based contrast agents (GBCA)s, which have potential safety concerns. PURPOSE: Test whether breast cancers imaged by 3T DCE breast MRI with 0.05 mmol/kg of gadobutrol are detectable. METHODS: Analysis of 3T DCE breast MRIs with half dose of gadobutrol from patients included in an IRB-approved and HIPPA-compliant prospective study of breast PET/MRI. Between 11/7/2014 and 3/2/2018, 41 consecutive women with biopsy-proven breast cancer that was at least 2 cm, multi-focal or multi-centric, had axillary metastasis, or had skin involvement who gave informed consent were included. Two breast radiologists independently recorded lesion conspicuity on a 4-point scale (0 = not seen, 1 = questionably seen, 2 = adequately seen, 3 = certainly seen), and measured the lesion. Size was compared between radiologists and with size on available mammogram, ultrasound, MRI, and surgical pathology. Inter-reader agreement was assessed by kappa coefficient for conspicuity. Lesion size comparisons were assessed using the Spearman rank correlation. RESULTS: In 40 patients (ages 28.4-80.5, 51.9 years), there were 49 cancers. 10.1% of lesions were 1 cm or less and 26.5% of lesions were 2 cm or less. Each reader detected 49/49 cancers. Conspicuity scores ranged from 2 to 3, mean 2.9/3 for both readers (p = 0.47). Size on half-dose 3T DCE-MRI correlated with size on surgical pathology (r = 0.6, p = 0.03) while size on mammogram and ultrasound did not (r = 0.25, p = 0.46; r = 0.25, p = 0.42). CONCLUSION: All breast cancers in this cohort, as small as 0.4 cm, were seen on 3T DCE breast MRI with 0.05 mmol/kg dose of gadobutrol.
BACKGROUND: Dynamic contrast enhanced (DCE) breast MRI is highly sensitive for breast cancer and requires gadolinium-based contrast agents (GBCA)s, which have potential safety concerns. PURPOSE: Test whether breast cancers imaged by 3T DCE breast MRI with 0.05 mmol/kg of gadobutrol are detectable. METHODS: Analysis of 3T DCE breast MRIs with half dose of gadobutrol from patients included in an IRB-approved and HIPPA-compliant prospective study of breast PET/MRI. Between 11/7/2014 and 3/2/2018, 41 consecutive women with biopsy-proven breast cancer that was at least 2 cm, multi-focal or multi-centric, had axillary metastasis, or had skin involvement who gave informed consent were included. Two breast radiologists independently recorded lesion conspicuity on a 4-point scale (0 = not seen, 1 = questionably seen, 2 = adequately seen, 3 = certainly seen), and measured the lesion. Size was compared between radiologists and with size on available mammogram, ultrasound, MRI, and surgical pathology. Inter-reader agreement was assessed by kappa coefficient for conspicuity. Lesion size comparisons were assessed using the Spearman rank correlation. RESULTS: In 40 patients (ages 28.4-80.5, 51.9 years), there were 49 cancers. 10.1% of lesions were 1 cm or less and 26.5% of lesions were 2 cm or less. Each reader detected 49/49 cancers. Conspicuity scores ranged from 2 to 3, mean 2.9/3 for both readers (p = 0.47). Size on half-dose 3T DCE-MRI correlated with size on surgical pathology (r = 0.6, p = 0.03) while size on mammogram and ultrasound did not (r = 0.25, p = 0.46; r = 0.25, p = 0.42). CONCLUSION: All breast cancers in this cohort, as small as 0.4 cm, were seen on 3T DCE breast MRI with 0.05 mmol/kg dose of gadobutrol.
Authors: Christiane K Kuhl; Simone Schrading; Kevin Strobel; Hans H Schild; Ralf-Dieter Hilgers; Heribert B Bieling Journal: J Clin Oncol Date: 2014-06-23 Impact factor: 44.544
Authors: Yaqi Shen; Frank L Goerner; Christopher Snyder; John N Morelli; Dapeng Hao; Daoyu Hu; Xiaoming Li; Val M Runge Journal: Invest Radiol Date: 2015-05 Impact factor: 6.016
Authors: Debra L Monticciolo; Mary S Newell; Linda Moy; Bethany Niell; Barbara Monsees; Edward A Sickles Journal: J Am Coll Radiol Date: 2018-01-19 Impact factor: 5.532
Authors: Li Feng; Robert Grimm; Kai Tobias Block; Hersh Chandarana; Sungheon Kim; Jian Xu; Leon Axel; Daniel K Sodickson; Ricardo Otazo Journal: Magn Reson Med Date: 2013-10-18 Impact factor: 4.668